Ongoing Assessments & Recent Research.
Easy access to our work
Covid-19
Jun 2026Friedreich’s Ataxia
Jan 2027Hypertension
Oct 2026Narcolepsy
May 2026Parkinson’s Disease
Oct 2026Featured News & Insights.
Learn about our latest work.
Institute for Clinical and Economic Review to Assess Treatments for Friedreich’s Ataxia
Report will be subject of New England CEPAC meeting in January 2027; Draft Scoping Document open to public comment until June 16, 2026.
05/26/2026Institute for Clinical and Economic Review Publishes Protocol for Annual Launch Price and Access Report
Survey for manufacturer pricing data now available.
05/04/2026Institute for Clinical and Economic Review Releases Evidence Report on Treatment for Narcolepsy
Oveporexton provides a net health benefit compared to currently available treatments; therapy would be cost effective if priced between $50,400 and $59,400 per year.
04/29/2026Our Origin Story.
Dr. Steve Pearson explains why he founded an organization to advance the use of evidence to improve health care affordability and access for all patients and their families.
The ICER Impact.
New York Medicaid pursued discounts, many of which were in line with ICER reports, which have saved the state over $500 million
Engaged with over 400 patient groups and patient reps
The ICER-developed Clinical trial Diversity Rating (CDR) Tool presents a framework for evaluating the demographic diversity of clinical trial populations in a consistent, transparent manner leading to an overall diversity rating. Learn more.
Current
Policy Papers.
Easy access to our latest policy papers
Strengthening the FDA’s Accelerated Approval Pathway: Progress and Unfinished Business
ICER, in collaboration with Verdant Research, will publish a new white paper that examines the evolution – and perception – of the FDA accelerated approval pathway. The paper, entitled, “Strengthening the FDA’s Accelerated Approval Pathway: Progress and Unfinished Business,” will review recent regulatory and market changes and propose several policy options that focuses on improvements that could be made by regulators, payers and manufacturers.
Launch Price and Access Report: Drug Approvals from 2022-2024
ICER conducted a new analysis it plans to release on an annual basis titled the “Launch Price and Access Report” which examines launch pricing for FDA-approved treatments. This report reviewed the affordability and access of the treatments and their value to the overall health system.
Special Assessment to Inform CMS Drug Price Negotiation: Vedolizumab (Entyvio®)
ICER is developed a special report for the Centers for Medicare & Medicaid Services on a therapy for treating Crohn’s disease and ulcerative colitis. This report was submitted to CMS as part of the 2026 public comment process defined in CMS guidance on Medicare Drug Price Negotiations for price applicability year 2028.